In contrast, a CRC-specific evaluation of patients treated with first-line FOLFIRI plus cetuximab or bevacizumab in the FIRE-3 trial16 suggested that patients with CH, in particular DNMT3A alterations, actually had an improved OS but no differences in PFS in this treatment setting. The gene discussed is DNMT3A; the disease is cyclic hematopoiesis.